Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology

Gregory Renza, an analyst from Truist Financial, maintained the Buy rating on CG Oncology, Inc.. The associated price target was raised to $66.00.

Gregory Renza has given his Buy rating due to a combination of factors tied to the accelerated clinical and commercial trajectory of Creto in non–muscle invasive bladder cancer (NMIBC). He highlights that the pivotal PIVOT-006 trial in intermediate-risk NMIBC will now deliver topline data about a year earlier than previously expected, suggesting strong physician enthusiasm and faster potential market entry. Renza also underscores that Creto’s opportunity in intermediate-risk disease is particularly attractive, given his higher peak sales assumptions relative to high-risk NMIBC, the larger eligible patient pool, and a less congested competitive field.

Renza further emphasizes that the trial design, which uses surveillance as the control arm, sets a relatively modest efficacy hurdle and, combined with Creto’s prior activity in similar patient subsets, supports a high probability of demonstrating superior recurrence-free survival. He views the early completion of enrollment in PIVOT-006 as a positive signal for real-world adoption and as a supportive indicator for the planned commercial rollout in high-risk BCG-unresponsive NMIBC beginning in late 2026. Alongside these clinical and strategic advantages, he advances his commercialization timeline by about one year and raises his price target to $66, reinforcing his conviction that CG Oncology’s risk/reward profile justifies a Buy rating.

In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $85.00 price target.